RT Journal Article
T1 Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients
A1 Grau, Santiago
A1 Vela, José Miguel
A1 Gurt, Alba
A1 Barceló Vidal, Jaime
A1 Ojeda, Fabiola
A1 López, Iago
A1 Gómez García, Laura
A1 Loza García, María Isabel
A1 Martín García, Elena
A1 Maldonado, Rafael
A1 Monfort, Jordi
K1 SIGMAR1-based therapy
K1 COVID-19
K1 Treatment
PB Elsevier
YR 2024
FD 2024-02
LK https://hdl.handle.net/10347/45285
UL https://hdl.handle.net/10347/45285
LA eng
NO Santiago Grau, José Miguel Vela, Alba Gurt, Jaime Barceló-Vidal, Fabiola Ojeda, Iago López, Laura Gómez-García, María Isabel Loza, Elena Martín-García, Rafael Maldonado, Jordi Monfort, Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients, Journal of Infection, Volume 88, Issue 2, 2024, Pages 187-190, ISSN 0163-4453, https://doi.org/10.1016/j.jinf.2023.11.008
NO This work was supported by the Spanish “Minsterio de Ciencia e Innovación (MICIN), Agencia Estatal de Investigación (AEI)” (PID2020-120029GB-I00/MICIN/AEI/10.13039/501100011033) to RM; the “Generalitat de Catalunya, AGAUR” (2017 SGR-669) to RM; the “ICREA-Acadèmia” (2020) to RM; and the Spanish “Instituto de Salud Carlos III, RETICS-RTA” (RD16/0017/0020) to RM. We gratefully acknowledge grant support from Xunta de Galicia through the call for proposals RESCATA-COVID (IN845D 2020/19) and the European Regional Development Fund (ERDF). This work has also been co-financed by the Ministry of Science and Innovation, Spain, with funds from the European Union NextGenerationEU (PRTRC17.I1) and the Autonomous Community of Galicia within the framework of the 2023 Biotechnology Plan Applied to Health. Finally, this work received partial financial support from Esteve Pharmaceuticals S.A.
DS Minerva
RD 28 abr 2026